Chemir Launches IQsynthesis - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Chemir Launches IQsynthesis


ePT--the Electronic Newsletter of Pharmaceutical Technology

Untitled Document

Chemir Launches IQsynthesis

Patricia Van Arnum

St. Louis, MO (Sept. 15)—Chemir Analytical Services (Maryland Heights, MO, www.chemir.com) has launched IQsynthesis (www.IQsynthesis.com), formerly known as Gateway Chemical Technology, Inc. Chemir acquired Gateway Chemical Technology, which provides custom synthesis and process development services, in May 2006.

“Clients have been requesting synthetic chemistry services, and we sought an acquisition to best fill this need,” explains Shri Thanedar, CEO of Chemir Analytical Services. 

IQsynthesis offers synthesis services for pharmaceutical intermediates; bioorganic compounds; and specialty, fine, and agrochemicals. Other services include synthesis of analytical standards, metabolites, tox lot batches, stable isotope-labeled compounds, intermediates, custom surfactants, combinational platforms, extraction and purification of natural products, and process development. Plans are underway to expand laboratory space and staff as well as develop infrastructure and systems for CGMP-regulated synthesis.

The Chemir group of companies include IQsynthesis; Chemir Analytical Services; Azopharma, a pharmaceutical contract service provider; and CAS-MI, a laboratory serving the paints, coatings, and polymer industries. Total sales for the company are expected to reach $24 million in 2006, with an anticipated goal of reaching $50 million by 2009.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
29%
Attracting a skilled workforce
26%
Obtaining/maintaining adequate financing
13%
Regulatory compliance
32%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here